In this report, we described an infant with both partial biotinidase and IL-12Rβ1 deficiencies as these two entities are rare and unrelated inherited disorders. One-month-old girl was diagnosed as partial biotinidase deficiency with newborn screening programme. Mutation analysis revealed a compound heterozygous mutation BTD: c.1330G>C (p.Val444Leu) / c.196_197dupCATC (p.Leu69HisfsTer24). At the age of 6 months, a nodule on her left axilla with purulent discharge was noticed which was related to BCG vaccination. A mutational analysis revealed a homozygous c.783+1G>A mutation on IL-12Rβ1 gene. Interferon-gamma and anti-tuberculosis treatment were initiated together and the nodule with purulent discharge regressed dramatically. Here, we want to emphasize consideration of coexistence of two rare autosomal recessively inherited diseases in a patient due to the high rate of consanguinity in our country.
Mendelian susceptibility to mycobacterial infections (MSMD) is an autosomal recessively inherited rare disease. Patients are susceptible to infections due to BCG (Bacilli Calmette-Guerin) vaccination, non-tuberculosis mycobacteria, and also Salmonella strains. IL-12 receptor beta 1 (IL-12Rβ1) deficiency is the most common form of MSMD and disease spectrum varies between local infections to systemic BCG infection. 1 Biotin is a vitamin that works as a cofactor of carboxylases in the organism. Biotinidase deficiency (BD) is an autosomal recessively inherited metabolic disease caused by disturbed recycling of biotin, leading to metabolic acidosis, cutaneous and neurological manifestations together with specific laboratory signs. 2 Additionally, impaired T cell function causes immune deficiency and lead to recurrent infections. 3 As a result of high consanguinity rate, BD is a frequently seen as inborn error of metabolism in Turkey. 4 Here, we present an infant with BCG lymphadenitis (BCG-itis) due to IL-12Rβ1 deficiency caused by a homozygous mutation in the IL12Rβ1 gene and partial BD due to compound heterozygous mutation in the BTD gene.
Case Report
A 1-month-old girl was referred to our hospital for the confirmation of BD which was detected by the national newborn screening program. She was born 3300 grams, at 39 weeks of gestation without a problem. Her parents were first degree cousins and she had a healthy brother. Otherwise the family history was unremarkable for an inherited disease, immune deficiencies or child death with an unknown cause. Umbilical cord separation occurred on fifth day of life. Her growth parameters, neuromotor development, and physical examination findings were fully normal for her age. She had no clinical symptoms or signs of BD. Serum biotinidase activity was measured as 2.39 U/L (N: 3.8-13.3). Biotin replacement was started at a dose of 5 mg/day for partial BD. Serum amino acids, acylcarnitine profile and urinary organic acid analysis were normal. Molecular analysis detected a compound heterozygous mutation in the BTD gene: 1 ). With biotin replacement therapy she was healthy until the age of six months, when the family was first aware of a lymphadenopathy with a diameter of 2x2 cm in her left axillary region which was persisting for two weeks. Detailed examination of the patient showed purulent discharge from the BCG scar on her left shoulder with multiple lymph nodes and a lesion consistent with an abscess up to 2 cm in diameter in the left axillary region. She had been vaccinated with BCG at the age of 2 months. Laboratory examination revealed a mild hypochromic microcytic anemia with normal results of acute phase reactants (erythrocyte sedimentation rate: 12 mm/h; C-reactive protein: 0.33 mg/L). When the tuberculin test was positive (12x13 mm), anti-mycobacterial treatment with isoniazid, rifampicin, and etambutol was initiated. The patient was also evaluated for a possible IL-12Rβ1 deficiency. Mutation analysis put forward a homozygous NM_005535.2 c.783+1G>A mutation on IL12Rβ1 gene. Interferon-gamma (IFNɣ) therapy was added to the treatment. After this combined therapy the patient's lymphadenopathies, abscess, and the purulent drainage regressed dramatically. At the last visit, the patient was 1-year-old and had no health problems.
We obtained the informed consent that was obtained from the parents.
Discussion
In this report, we present an infant with co-existing, two rare hereditary disorders: biotinidase and IL-12RβI deficiencies. The prevalence of BD is about 1 in 60000 live births and the prevalence of IL-12Rβ1 deficiency is about 1 in 100000-1000000 births. Both BD and IL-12Rβ1 deficiency are rare diseases and the probability of their co-existence is very low. Indeed, high consanguinity rates of our country may increase this possibility.
Biotinidase deficiency was first defined in biotin responsive multiple carboxylase deficiency by Gompertz et al. in 1971 . 5 Consequently, BTD gene has been discovered and accepted as the responsible factor for BD. Up to date, more than 100 pathogenic mutations on Fig. 1. A mutation in the IL-12Rβ1 gene.
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Coexistence of IL-12 Receptor β1 and Biotinidase Deficiencies BTD gene have been described. 6 The disease is characterized by convulsions, hypotonia, psychomotor retardation, progressive deafness and blindness. In addition to these clinical findings, skin lesions and infections due to immunological dysfunction are frequently seen. Signs and symptoms may begin in infancy. As late diagnosis and treatment of BD can cause irreversible neurological, ophthalmological damages, sensorineural hearing loss, blindness and autistic behaviors, neonatal screening programs are crucial. 4 Newborn screening program for BD was initiated in 2008 in Turkey. Our patient with partial BD was detected in the first month of age before any symptoms occurred and followed as a healthy infant with 5 mg/d biotin supplementation to the age of six months when a BCG lymphadenitis was noticed. Biotinidase deficiency may cause cellular immune deficiency. 3 However, the most important host defense against intracellular pathogens like Mycobacteria and Salmonella is cellular immunity and the basic mechanism is macrophage activation via type 1 cytokines. Amongst them, the most important cytokine is IFNɣ. T helper lymphocytes and natural killer cells produce IFNɣ as a consequence of IL12 binding to IL-12Rβ1 and IL-12Rβ2 on the cells' surface. 1 So, we investigated the patient for IFNɣ deficiency, and found a homozygous mutation on IL12Rβ1 gene. Generally, the response to antimycobacterial therapy is quite satisfactory in IL-12Rβ1 deficiency. But, it is recommended to add IFNɣ to antimycobacterial therapy in order to shorten the treatment period and decrease the risk of tendency to recurrent mycobacterial infections with high mortality rates in symptomatic patients. Although our patient's response to antituberculosis therapy was sufficient, the additional problem of BD, which also can lead to cellular immune dysfunction, highlighted us about adding IFNɣto the treatment. To date a direct genetic link between immune disorders including IL-12Rβ1 deficiency and BD has not been reported in the literature. The existing familial relationship between the parents was of note. IL12Rβ1 and BTD gene was examined in the family members, and same heterozygous mutation was found in the parents. They were unaware of their condition as carriers and transmitted both diseases to their children.
As there is not any screening program for IL-12Rβ1 deficiency in the world, the diagnosis of IL-12Rβ1 deficiency was frequently thought after a BCG lymphadenitis. 7 Identifying the underlying problem of patients with BCG lymphadenitis is important. Because prolonged and aggressive antituberculosis treatment is essential for the patients with IL-12Rβ1 deficiency. 8, 9 Our patient was also diagnosed as IL-12Rβ1 deficiency after a BCG lymphadenitis, and antituberculosis treatment with three drugs was initiated.
Although parents are relatives, BTD gene has compound heterozygote. This is because of high frequency of heterozygote carriers in the population. Carrier frequency in the general population is approximately one in 120. 10
In conclusion, coexistence of two different hereditary disorders should be in mind, in patients when the clinical signs cannot be explained satisfactorily with one disease, especially in countries like Turkey, where parental consanguinity rate is high. One consequence of familial relationship between the parents is an increase of recessive disease. We wanted to draw attention to the coexistence of these two rare hereditary diseases that have not been previously reported in the literature. Additionally, lymphadenitis following BCG vaccination requires investigation for immune deficiencies including IL-12Rβ1 deficiency. This is extremely important in countries where tuberculosis prevalence is high and BCG vaccination is routine.
